Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A clinical trial to study the effects of two drugs, Folfox and CT-011 in patients with cancer of large intestine.

ABSTRACT: Intervention1: CT-011: CT-011 (Monoclonal Antibody), 3.0 mg/kg for days 0, 4, 8, 12, 24, 36, 48, 60, 76 along with the combination of FOLFOX . Dose Value; 3mg/kg (OD). Frequency: Every 2 weeks Route: Intravenous TOTAL duration of therapy: 32 months Control Intervention1: Chemotherapy regimens include FOLFOX4 or mFOLFOX6 (5-FU, oxaliplatin: Humanized monoclonal antibody. Treatment details similar as of Intervention. Primary outcome(s): The primary endpoint will be the median progression free survival in patients treated with CT-011 plus FOLFOX compared to that of patients treated with FOLFOX alone. [ Time Frame: 32 months ]Timepoint: Within 32months following the first CT-011 treatment Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label

DISEASE(S): Patients With Colorectal Adenocarcinoma Previously Untreated For Metastatic Disease

PROVIDER: 2575782 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Rattus norvegicus

Project description:Rat exposure to RDX (3mg/kg or 18mg/kg; 0, 4, 24, 48 hr)

| PRJNA113417 | ENA

Transcription profiling of rat tissues dosed with AMG A or AMG B

Project description:To evaluate and characterize gene expression changes and toxicity following oral gavage administration of AMG A & AMG B in male Sprague Dawley rats. Experiment Overall Design: This toxicogenomics study is designed to determine the toxicity and gene expression of AMG A and AMG B dosed orally daily (AMG A at 0mg/kg, 3mg/kg and 30 mg/kg and AMG B at 0mg/kg, 3mg/kg and 60mg/kg) for 1, 4 and 14 days. These doses are expected to produce mild and moderate changes in clinical pathology and histology associated with the pharmacologic antiangiogenic effect.

2008-06-11 | E-GEOD-10015 | biostudies-arrayexpress

Bis-(2-chloroethyl) sulfide exposure time course and dose response in the rat lung

Project description:Male Sprague-dawley rats were exposed to saline, isopropyl alcohol, 1mg/kg, 3mg/kg or 6 mg/kg sulfur mustard for 30 min, 1 hr, 3 hr, 6 hr, or 24 hr before analysis of lung tissue by oligonucleotide array analysis. Keywords = sulfur mustard Keywords = rat Keywords = lung Keywords = bis-(2-chloroethyl) sulfide Keywords: ordered

2004-12-20 | GSE1888 | GEO

A clinical trial to study the effects of two drugs, R-TPR-023 and Avastinâ?¢ in patients with Metastatic colorectal cancer

Project description:Intervention1: R-TPR-023: Dose: 5 mg/kg, Frequency: Every 2 weeks, Route of Administration: Intravenously, Duration: 3 years. Control Intervention1: Avastinâ?¢: Dose: 5 mg/kg, Frequency: Every 2 weeks, Route of Administration: Intravenously, Duration: 3 years Primary outcome(s): Outcome Name: Efficacy will be assessed as Objective Response Rate (Complete Response and Partial Response) by RECIST 1.1 criteria at 25 weeksTimepoint: 25 weeks Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Open Label

| 2574628 | ecrin-mdr-crc

A phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients with metastatic colorectal cancer

Project description:Intervention1: Masitinib, FOLFIRI: Masitinib will be taken orally, daily at 6mg/kg/day. FOLFIRI will be administered every 2 weeks Control Intervention1: Placebo, FOLFIRI: Placebo will be taken orally, daily. FOLFIRI will be administered every 2 weeks Primary outcome(s): Overall Survival (OS)Timepoint: till death or last follow up Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant and Investigator Blinded

| 2577140 | ecrin-mdr-crc

Comparison of two drugs ( inj dexmedetomidine and inj clonidine) in terms of recovery from anaesthesia

Project description:Intervention1: Dexmedetomidine and Clonidine: Drugs to be given before the end of surgery as infusion over 10 minutes Control Intervention1: Injection Dexmedetomidine: Injection Dexmedetomidine 1 Microgram / Kg at the end of surgery as infusion over 10 minutes Control Intervention2: Injection Clonidine: Injection Clonidine 3 Microgram /Kg as infusion over 10 minutes at the end of surgery Primary outcome(s): Haemodynamic stabilityTimepoint: Intraoperatively (1- 3 hours) Study Design: Randomized, Parallel Group, Placebo Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant, Investigator and Outcome Assessor Blinded

| 29486 | ecrin-mdr-crc

Transcription profiling of lung tissue of male Sprague Dawley rats after exposure to saline, isopropyl alcohol and sulfur mustard for 30 min, 1 hr, 3 hr, 6 hr, or 24 hr

Project description:Male Sprague-Dawley rats were exposed to saline, isopropyl alcohol, 1mg/kg, 3mg/kg or 6 mg/kg sulfur mustard for 30 min, 1 hr, 3 hr, 6 hr, or 24 hr before analysis of lung tissue by oligonucleotide array analysis.

2007-09-14 | E-GEOD-1888 | biostudies-arrayexpress

MS-based sequencing of the anti-FLAG-M2 antibody

Project description:We demonstrate a method for direct de novo sequencing of monoclonal IgG from the purified antibody products. The method uses a panel of multiple complementary proteases to generate suitable peptides for de novo sequencing by LC-MS/MS in a bottom-up fashion. Furthermore, we apply a dual fragmentation scheme, using both stepped high-energy collision dissociation (stepped HCD) and electron transfer high-energy collision dissociation (EThcD) on all peptide precursors. The method achieves full sequence coverage of the monoclonal antibody Herceptin, with an accuracy of 98% in the variable regions. We applied the method to sequence the widely used anti-FLAG-M2 mouse monoclonal antibody, which we successfully validated by remodeling a high-resolution crystal structure of the Fab and demonstrating binding to a FLAG-tagged target protein in Western blot analysis. The method thus offers robust and reliable sequences of monoclonal antibodies.

2021-01-11 | PXD023419 | Pride

Comparison of two regimens of total intravenous anaesthesia for time to recovery from anaesthesia.

Project description:Intervention1: ADBIULFAUIPQP: FNRREUIQFNQI;QEIO;EQGBGR Intervention2: propofol and dexmedetomidine: infusion dexmedetomidine @1mcg/kg over 10 min folowed by infusion dexmedetomidine 0.5mcg/kg/hr. infusion propofol 200mcg/kg/min to maintain a BIS of 40-50 Control Intervention1: EWFVUKFVUY: W2VFUYO Control Intervention2: Propofol and Ketamine: INFUSION KETAMINE @1MG/KG OVER 10 MINS FOLLOWED BY INFUSION KETAMINE 0.5MG/KG/HR INFUSION PROPOFOL 200MCG/KG/MIN TITRATED TO MAINTAIN A BIS OF 40-50 Primary outcome(s): Time taken to achieve Modified Aldrete Score of â?¥9 (MeanÂ±SD) using propofol with ketamine or dexmedetomidineTimepoint: postoperative every minute till Modified Adrette Score is more than or equal to 9 Study Design: Randomized, Parallel Group, Active Controlled Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Sequentially numbered, sealed, opaque envelopes Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

| 2601412 | ecrin-mdr-crc

A Clinical trial to evaluate the pharmacokinetics, safety, efficacy and immunogenicity of Bmab-100 and Avastin in patients with metastatic colorectal cancer

Project description:Intervention1: Bmab-100: administered intravenously 7.5 mg/kg/body weight once every 3 weeks for 6 cycles. Control Intervention1: Avastin (Roches bevacizumab): to administer 7.5mg/kg once evry 3 weeks for 6 cycles Primary outcome(s): Single dose pharmacokinetic parameters for Bmab-100 and AvastinÂ in terms of AUC0-t and Cmax [Cycle 1]Timepoint: Single dose pharmacokinetic parameters for Bmab-100 and AvastinÂ in terms of AUC0-t and Cmax [Cycle 1] Study Design: Randomized, Parallel Group Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:Centralized Blinding and masking:Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded

| 2576020 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data